Evidence map›Paper›PMID 20334660›Full record

ArticleBMC immunology2010

In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.

Kwang-il Jeong, Susan Chapman-Bonofiglio, Pradeep Singh, Jongo Lee, Saul Tzipori, Abhineet S Sheoran

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Thrombotic microangiopathies.ISRN hematology · 2012
    Article
  7. Shiga toxin pathogenesis: kidney complications and renal failure.Current topics in microbiology and immunology · 2012
    Review
  8. Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy.Toxicon : official journal of the International Society on Toxinology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kwang-il JeongDepartment of Biomedical Sciences, Cummings School of Veterinary Medicine, Tufts University, Medford, MA 02155 USA.
Susan Chapman-Bonofiglio
Pradeep Singh
Jongo Lee
Saul Tzipori
Abhineet S Sheoran
Tufts University · USSoutheast Missouri State University · US

Funding

GENETICS AND ROLE OF ALGINATE IN P. AERUGINOSA INFECTIONR29AI030050 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GOLDBERG, JOANNA B. · 1991 to 1995
–
NIAID NIH HHS N01-AI-30050
6 · The paper itself

Abstract

backgroundShiga toxin 2 (Stx2), one of two Stx liberated by Stx-producing Escherichia coli, is composed of an A subunit monomer and a B subunit pentamer, and is directly linked with hemolytic uremic syndrome in children. The pentameric B subunit binds to its cell surface receptor Gb3 for toxin internalization, and the A subunit follows intracellular retrograde transport to the cytosol where its RNA N-glycosidase activity (RNA-NGA) shuts down the protein synthesis, and leads to cell death. The present study investigated the ability of 19 Stx2 A subunit-specific human monoclonal antibodies (HuMAbs) to neutralize the RNA-NGA, and the association this neutralizing activity with protection of HeLa cells and mice against Stx2-induced death.

resultsThe HuMAbs that were stronger inhibitors of RNA-NGA were also better at neutralizing Stx2 mediated HeLa cell death, and those that were weaker inhibitors of RNA-NGA activity were also weaker in protecting HeLa cells. These results suggest that the ability of an A subunit-specific antibody to block the RNA-NGA of the toxin is directly related to its ability to neutralize Stx2-mediated HeLa cell death. However, with the exception of the best RNA-NGA blocking antibodies 5C12 and 2F10, the efficacies of antibody neutralization of RNA-NGA of Stx2 did not correlate with their in vivo protective efficacies. The HuMAb 6C3, which neutralized RNA N-glycosidase activity of Stx2 less effectively than the HuMAbs 6D8 and 6B7, protected 100% of the mice against Stx2 challenge at 50 microg/mouse dose. In contrast, the HuMAbs 6D8 and 6B7, which neutralized RNA N-glycosidase activity of Stx2 more effectively than 6C3, protected 20% and 0% mice at that dose, respectively.

conclusionsThe neutralization efficiency of the RNA-NGA of Stx2 by A subunit-specific antibodies correlate strongly with their abilities to protect HeLa cells against Stx2-mediated toxicity but only the strongest RNA-NGA-neutralizing antibodies correlate very well with both protecting HeLa cells and mice against Stx2 challenge.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBlotting, WesternHeLa CellsHumansMiceRibosome Inactivating ProteinsShiga Toxin 2Antibodies, MonoclonalAntibodies, NeutralizingRibosome Inactivating ProteinsShiga Toxin 2

Identifiers

PMID20334660
PMCPMC2859748
OpenAlexW2060146966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.